The withdrawal of Vioxx had substantial public health implications. An estimated 88,000 to 140,000 excess cases of serious coronary heart disease were attributed to Vioxx in the United States alone. This event underscored the importance of pharmacovigilance and the need for robust post-marketing surveillance systems to detect adverse drug reactions early.
